about
Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments.The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer.Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines.Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer.Altered mucosal expression of microRNAs in pediatric patients with inflammatory bowel disease.Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models.[Simplified, low-cost gene expression profiling for the prediction of outcome in breast cancer based on routine histologic specimens].Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers.Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer.Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumorsHigh on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapyDetection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutationsThe genomic imprint of cancer therapies helps timing the formation of metastasesAnalysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate CancerCorrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors
P50
Q34541259-D0639593-ECD2-40B1-937B-525367B3C56CQ34611524-97117C35-1BBD-4B6C-8C5D-C12ADC72F900Q34651354-4346CFDB-4B3A-4B41-BF46-193CBCF6ED84Q35161221-478428E0-8268-47BA-9199-4392978019C2Q39026427-CAF99DFA-BD70-43E8-8BAE-7C0787516F0FQ39184305-D03E43A8-AE37-445D-A1C4-C5ABA8A7EE71Q46934740-24A007BC-3DFA-4DA5-8534-18142069B2F1Q49922749-6C276A0E-302E-483F-AE6E-890ACC0DCDB7Q55431246-E9C66132-1BB2-4420-947E-525812B688F9Q57813899-AD02DBEC-4AAB-457F-87A6-667AD1BD36BEQ86988470-7604411E-C941-472D-94E0-51BE4D578481Q89766252-5AFAC107-5BD2-4DD4-AA8F-153833497B84Q91265658-58E6EC8E-4324-4516-847B-A0F6D699B1A9Q92011460-E9A38C8D-C859-40BA-A0F7-CCC2FFEE6613Q92720783-7D78C129-9882-45E3-85D1-E95B4D6FD63D
P50
description
(?) kutatóorvos, onkológus
@hu
Hongaars onderzoekster
@nl
researcher
@en
հետազոտող
@hy
name
Sztupinszki Zsófia
@hu
Zsófia Sztupinszki
@ast
Zsófia Sztupinszki
@en
Zsófia Sztupinszki
@es
Zsófia Sztupinszki
@nl
Zsófia Sztupinszki
@sl
type
label
Sztupinszki Zsófia
@hu
Zsófia Sztupinszki
@ast
Zsófia Sztupinszki
@en
Zsófia Sztupinszki
@es
Zsófia Sztupinszki
@nl
Zsófia Sztupinszki
@sl
prefLabel
Sztupinszki Zsófia
@hu
Zsófia Sztupinszki
@ast
Zsófia Sztupinszki
@en
Zsófia Sztupinszki
@es
Zsófia Sztupinszki
@nl
Zsófia Sztupinszki
@sl
P106
P1153
55360856200
P1960
ZNe91SwAAAAJ
P21
P2492
P27
P31
P496
0000-0002-8691-4086